• Spero Therapeutics appointed Amy Rock chief regulatory and quality officer.
• Rock previously served as senior vice president, regulatory sciences, at Vir Biotechnology, bringing more than 25 years of biopharmaceutical experience.
• Dae Gon Ha joins as senior vice president, corporate development, previously leading strategy and business development at Fulcrum Therapeutics.
• Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, following 11 years of service.
• Other executive leadership team members will assume Keutzer's responsibilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800PRIMZONEFULLFEED9852782) on October 26, 2026, and is solely responsible for the information contained therein.